- Home
- GYRE vs SHLS Comparison
GYRE vs SHLS Comparison
Compare GYRE & SHLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GYRE
- SHLS
- Stock Information
- Founded
- GYRE 2002
- SHLS 1996
- Country
- GYRE United States
- SHLS United States
- Employees
- GYRE N/A
- SHLS N/A
- Industry
- GYRE Biotechnology: Pharmaceutical Preparations
- SHLS Semiconductors
- Sector
- GYRE Health Care
- SHLS Technology
- Exchange
- GYRE Nasdaq
- SHLS Nasdaq
- Market Cap
- GYRE 897.1M
- SHLS 978.0M
- IPO Year
- GYRE N/A
- SHLS 2021
- Fundamental
- Price
- GYRE $7.57
- SHLS $5.81
- Analyst Decision
- GYRE
- SHLS Buy
- Analyst Count
- GYRE 0
- SHLS 24
- Target Price
- GYRE N/A
- SHLS $9.44
- AVG Volume (30 Days)
- GYRE 159.6K
- SHLS 5.6M
- Earning Date
- GYRE 08-12-2025
- SHLS 08-05-2025
- Dividend Yield
- GYRE N/A
- SHLS N/A
- EPS Growth
- GYRE N/A
- SHLS N/A
- EPS
- GYRE 0.02
- SHLS 0.11
- Revenue
- GYRE $100,643,000.00
- SHLS $388,762,000.00
- Revenue This Year
- GYRE $21.04
- SHLS $11.35
- Revenue Next Year
- GYRE $89.64
- SHLS $11.58
- P/E Ratio
- GYRE $95.15
- SHLS $53.46
- Revenue Growth
- GYRE N/A
- SHLS N/A
- 52 Week Low
- GYRE $6.11
- SHLS $2.71
- 52 Week High
- GYRE $19.00
- SHLS $7.00
- Technical
- Relative Strength Index (RSI)
- GYRE 47.42
- SHLS 56.47
- Support Level
- GYRE $7.09
- SHLS $5.43
- Resistance Level
- GYRE $7.63
- SHLS $6.16
- Average True Range (ATR)
- GYRE 0.40
- SHLS 0.34
- MACD
- GYRE 0.03
- SHLS -0.01
- Stochastic Oscillator
- GYRE 42.74
- SHLS 40.43
About GYRE Gyre Therapeutics Inc.
Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.
About SHLS Shoals Technologies Group Inc.
Shoals Technologies Group is a provider of electrical balance of system solutions for solar energy projects, primarily in the United States. EBOS encompasses components that are necessary to carry electric current produced by solar panels to an inverter. The products are sold principally to engineering, procurement, and construction firms that build solar energy projects.